Targeting cell death signalling in cancer: minimising 'Collateral damage'

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer cells often evade apoptosis, a natural cell death process.
• Targeting apoptosis is a key cancer therapy strategy, involving pathways like TRAIL signaling and proteins such as BCL-2 and IAP.
• Many cancers retain intact apoptotic pathways that could be exploited for treatment.

Purpose of the Study:

• To review current anti-cancer therapies targeting apoptosis.
• To discuss the unforeseen toxicities and adverse effects of modulating apoptotic pathways.
• To emphasize the need for a deep understanding of apoptotic and non-apoptotic functions of drug targets.

Main Methods:

• Literature review of apoptosis-targeting cancer therapies.
• Analysis of signaling pathways involved in apoptosis (TRAIL, BCL-2, IAP).
• Discussion of mechanistic insights into apoptotic and non-apoptotic protein functions.

Main Results:

• Modulating apoptosis for cancer treatment faces challenges due to potential dose-limiting toxicities.
• A comprehensive understanding of both apoptotic and non-apoptotic signaling is essential for effective therapy.
• Unblocking intact apoptotic pathways can efficiently kill cancer cells.

Conclusions:

• Targeting apoptosis requires a thorough understanding of its complex regulatory mechanisms to mitigate adverse effects.
• Novel strategies are needed to sensitize cancer cells to apoptosis, enhancing existing therapies.
• Combining novel targeted agents with improved apoptosis induction holds promise for more effective cancer treatment.